Foliar mycoendophytome of an endemic plant of the Mediterranean biome (Myrtus communis) reveals the dominance of basidiomycete woody saprotrophs

The true myrtle, Myrtus communis, is a small perennial evergreen tree that occurs in Europe, Africa, and Asia with a circum-Mediterranean geographic distribution. Unfortunately, the Mediterranean Forests, where M. communis occurs, are critically endangered and are currently restricted to small fragmented areas in protected conservation units. In the present work, we performed, for the first time, a metabarcoding study on the spatial variation of fungal community structure in the foliar endophytome of this endemic plant of the Mediterranean biome, using bipartite network analysis as a model. The local bipartite network of Myrtus communis individuals and their foliar endophytic fungi is very low connected, with low nestedness, and moderately high specialization and modularity. Similar network patterns were also retrieved in both culture-dependent and amplicon metagenomics of foliar endophytes in distinct arboreal hosts in varied biomes. Furthermore, the majority of putative fungal endophytes species were basidiomycete woody saprotrophs of the orders Polyporales, Agaricales, and Hymenochaetales. Altogether, these findings suggest a possible adaptation of these wood-decaying fungi to cope with moisture limitation and spatial scarcity of their primary substrate (dead wood), which are totally consistent with the predictions of the viaphytism hypothesis that wood-decomposing fungi inhabit the internal leaf tissue of forest trees in order to enhance dispersal to substrates on the forest floor, by using leaves as vectors and as refugia, during periods of environmental stress.Comissión Interministerial de Ciencia y Tecnología (CICYT): AGL2008-00572. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior: 2330-10-5/CAPES. CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico of Brazil). Consejo Superior de Investigaciones Científicas (CSIC) and the European Social Funds

Taxonomia e variação geográfica das espécies do gênero Alouatta Lacépède (Primates, Atelidae) no Brasil Taxonomy and geographic variation of species of the genus Alouatta Lacépède (Primates, Atelidae) in Brazil

Neste estudo analisou-se a variação geográfica e não-geográfica de táxons de bugios, gênero Alouatta Lacépède, 1799, que ocorrem no Brasil, com o objetivo de esclarecer a taxonomia do grupo. Para a análise morfológica, examinou-se um total de 1.286 espécimes mantidos em cinco museus brasileiros e dois norte-americanos. O material consistiu basicamente de peles, crânios e ossos hióides; esqueletos e espécimes preservados em via úmida foram escassos. O estudo se baseou na análise qualitativa dos complexos morfológicos em adição a 18 morfométicos do crânio e osso hióide. Antes das decisões taxonômicas, elaborou-se um estudo de variação geográfica, sexual, ontogenética e individual. Reconheceu-se 10 espécies de Alouatta ocorrendo no Brasil, sendo a maioria definida por caracteres discretos, porém diagnósticos. São elas: Alouatta caraya (Humboldt, 1812), A. fusca (Geoffroy Saint-Hilaire, 1812), A. clamitans Cabrera, 1940, A. belzebul (Linnaeus, 1766), A. discolor (Spix, 1823), A. ululata Elliot, 1912; A. juara (Linnaeus, 1766), A. macconnelli (Humboldt, 1812), A. puruensis Lönnberg, 1941 e A. nigerrima Lönnberg, 1941. Alouatta macconnelli e A. clamitans mostraram notável variação geográfica na coloração da pelagem e algumas variáveis morfométricas (polimorfismo) o que dificultou as definições e limites dos táxons. Alouatta belzebul apresentou variação em mosaico na coloração da pelagem. Alouatta ululata e A. puruensis foram definidas pela presença de dicromatismo sexual na pelagem, mas este caráter pode ser um artefato e necessita estudos adicionais para corroborar sua validade. Sinonimizou-se Alouatta belzebul mexianae Hagmann, 1908 com A. discolor; e a validade de Alouatta seniculus amazonica Lönnberg 1941, não foi considerada.<br>In this monograph, was studied non-geographic and geographic variation of taxa of Howling Monkeys, genus Alouatta Lacépède, 1799, occuring in Brazil, in order to solve the taxonomy of the group. For the morphological analysis, were examined a total of 1,286 specimens kept in five Brazilian and two North-American museums. The material consisted mostly of skin, skull and hyoid bone; skeleton or fluid-preserved specimens were scarse. The study was based on qualitative analysis of the morphological complexes in addition 18 morphometric characters of the skull and hyoid bone. Prior to making taxonomic decisions, was conducted a study of geographic, sexual, ontogenetic, and individual variation. Were recognized ten species of Alouatta occuring in Brazil and most of them were defined by discrete, but diagnostic characters. The species are: Alouatta caraya (Humboldt, 1812), A. fusca (Geoffroy Saint-Hilaire, 1812), A. clamitans Cabrera, 1940, A. belzebul (Linnaeus, 1766), A. discolor (Spix, 1823), A. ululata Elliot, 1912; A. juara (Linnaeus, 1766), A. macconnelli (Humboldt, 1812), A. puruensis Lönnberg, 1941, and A. nigerrima Lönnberg, 1941. Alouatta macconnelli and A. clamitans showed noticeable geographic variation on pelage coloration and some morphometric characters (polymorphism) difficulting their definition and geographic limits. Alouatta belzebul presented an accentuated geographic mosaic variation on coat coloration. Alouatta ululata and A. puruensis were defined in presenting sexual dicromism on pelage, but this character can be an artefate due the small sample and both taxa need further studies to confirm their validity. Alouatta belzebul mexianae Hagmann, 1908 was sinonimized with A. discolor; and the validity of Alouatta seniculus amazonica Lönnberg 1941 was not considered

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60 countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V